S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
CVE:KHRN

Khiron Life Sciences Corp. (KHRN.V) Competitors

C$0.55
+0.02 (+3.77 %)
(As of 02/26/2021 04:00 PM ET)
Add
Compare
Today's Range
C$0.48
Now: C$0.55
C$0.56
50-Day Range
C$0.00
MA: C$0.43
C$0.64
52-Week Range
C$0.30
Now: C$0.55
C$0.90
Volume777,248 shs
Average Volume836,369 shs
Market CapitalizationC$82.59 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Khiron Life Sciences Corp. (KHRN.V) (CVE:KHRN) Vs. WLLW, LABS, DN, META, NRTH, and CSI

Should you be buying KHRN stock or one of its competitors? Companies in the industry of "drug manufacturers—specialty & generic" are considered alternatives and competitors to Khiron Life Sciences Corp. (KHRN.V), including Willow Biosciences Inc. (WLLW.TO) (WLLW), MediPharm Labs Corp. (LABS.TO) (LABS), Delta 9 Cannabis (DN), Meta Growth Corp. (META.V) (META), 48North Cannabis Corp. (NRTH.V) (NRTH), and (CSI) (CSI).

Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) and Khiron Life Sciences Corp. (KHRN.V) (CVE:KHRN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Valuation and Earnings

This table compares Willow Biosciences Inc. (WLLW.TO) and Khiron Life Sciences Corp. (KHRN.V)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Willow Biosciences Inc. (WLLW.TO)C$2,360.0078,260.42C$-32,036,529.00C($0.28)-5.77
Khiron Life Sciences Corp. (KHRN.V)C$8.01 million10.31C$-39,493,921.00C($0.26)-2.09

Willow Biosciences Inc. (WLLW.TO) has higher earnings, but lower revenue than Khiron Life Sciences Corp. (KHRN.V). Willow Biosciences Inc. (WLLW.TO) is trading at a lower price-to-earnings ratio than Khiron Life Sciences Corp. (KHRN.V), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Willow Biosciences Inc. (WLLW.TO) and Khiron Life Sciences Corp. (KHRN.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Willow Biosciences Inc. (WLLW.TO)N/AN/AN/A
Khiron Life Sciences Corp. (KHRN.V)N/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Willow Biosciences Inc. (WLLW.TO) and Khiron Life Sciences Corp. (KHRN.V), as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Willow Biosciences Inc. (WLLW.TO)0000N/A
Khiron Life Sciences Corp. (KHRN.V)0000N/A

Willow Biosciences Inc. (WLLW.TO) presently has a consensus target price of C$2.75, suggesting a potential upside of 69.75%. Khiron Life Sciences Corp. (KHRN.V) has a consensus target price of C$1.20, suggesting a potential upside of 118.18%. Given Khiron Life Sciences Corp. (KHRN.V)'s higher probable upside, analysts clearly believe Khiron Life Sciences Corp. (KHRN.V) is more favorable than Willow Biosciences Inc. (WLLW.TO).

Summary

Khiron Life Sciences Corp. (KHRN.V) beats Willow Biosciences Inc. (WLLW.TO) on 4 of the 6 factors compared between the two stocks.

MediPharm Labs Corp. (LABS.TO) (TSE:LABS) and Khiron Life Sciences Corp. (KHRN.V) (CVE:KHRN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Earnings & Valuation

This table compares MediPharm Labs Corp. (LABS.TO) and Khiron Life Sciences Corp. (KHRN.V)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm Labs Corp. (LABS.TO)C$62.40 million1.45C$-41,458,230.00C($0.30)-2.19
Khiron Life Sciences Corp. (KHRN.V)C$8.01 million10.31C$-39,493,921.00C($0.26)-2.09

Khiron Life Sciences Corp. (KHRN.V) has lower revenue, but higher earnings than MediPharm Labs Corp. (LABS.TO). MediPharm Labs Corp. (LABS.TO) is trading at a lower price-to-earnings ratio than Khiron Life Sciences Corp. (KHRN.V), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MediPharm Labs Corp. (LABS.TO) and Khiron Life Sciences Corp. (KHRN.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MediPharm Labs Corp. (LABS.TO)N/AN/AN/A
Khiron Life Sciences Corp. (KHRN.V)N/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and target prices for MediPharm Labs Corp. (LABS.TO) and Khiron Life Sciences Corp. (KHRN.V), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MediPharm Labs Corp. (LABS.TO)03102.25
Khiron Life Sciences Corp. (KHRN.V)0000N/A

MediPharm Labs Corp. (LABS.TO) presently has a consensus target price of C$1.98, suggesting a potential upside of 204.62%. Khiron Life Sciences Corp. (KHRN.V) has a consensus target price of C$1.20, suggesting a potential upside of 118.18%. Given MediPharm Labs Corp. (LABS.TO)'s higher probable upside, equities research analysts clearly believe MediPharm Labs Corp. (LABS.TO) is more favorable than Khiron Life Sciences Corp. (KHRN.V).

Summary

Khiron Life Sciences Corp. (KHRN.V) beats MediPharm Labs Corp. (LABS.TO) on 4 of the 7 factors compared between the two stocks.

Delta 9 Cannabis (TSE:DN) and Khiron Life Sciences Corp. (KHRN.V) (CVE:KHRN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Earnings & Valuation

This table compares Delta 9 Cannabis and Khiron Life Sciences Corp. (KHRN.V)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delta 9 CannabisC$48.48 million1.18C$-4,183,599.00C($0.04)-13.66
Khiron Life Sciences Corp. (KHRN.V)C$8.01 million10.31C$-39,493,921.00C($0.26)-2.09

Delta 9 Cannabis has higher revenue and earnings than Khiron Life Sciences Corp. (KHRN.V). Delta 9 Cannabis is trading at a lower price-to-earnings ratio than Khiron Life Sciences Corp. (KHRN.V), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Delta 9 Cannabis and Khiron Life Sciences Corp. (KHRN.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Delta 9 CannabisN/AN/AN/A
Khiron Life Sciences Corp. (KHRN.V)N/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and target prices for Delta 9 Cannabis and Khiron Life Sciences Corp. (KHRN.V), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Delta 9 Cannabis00014.00
Khiron Life Sciences Corp. (KHRN.V)0000N/A

Delta 9 Cannabis presently has a consensus target price of C$1.24, suggesting a potential upside of 121.43%. Khiron Life Sciences Corp. (KHRN.V) has a consensus target price of C$1.20, suggesting a potential upside of 118.18%. Given Delta 9 Cannabis' higher probable upside, equities research analysts clearly believe Delta 9 Cannabis is more favorable than Khiron Life Sciences Corp. (KHRN.V).

Summary

Delta 9 Cannabis beats Khiron Life Sciences Corp. (KHRN.V) on 5 of the 7 factors compared between the two stocks.

Meta Growth Corp. (META.V) (CVE:META) and Khiron Life Sciences Corp. (KHRN.V) (CVE:KHRN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Profitability

This table compares Meta Growth Corp. (META.V) and Khiron Life Sciences Corp. (KHRN.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Meta Growth Corp. (META.V)N/AN/AN/A
Khiron Life Sciences Corp. (KHRN.V)N/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and target prices for Meta Growth Corp. (META.V) and Khiron Life Sciences Corp. (KHRN.V), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Meta Growth Corp. (META.V)0000N/A
Khiron Life Sciences Corp. (KHRN.V)0000N/A

Khiron Life Sciences Corp. (KHRN.V) has a consensus target price of C$1.20, suggesting a potential upside of 118.18%. Given Khiron Life Sciences Corp. (KHRN.V)'s higher probable upside, analysts clearly believe Khiron Life Sciences Corp. (KHRN.V) is more favorable than Meta Growth Corp. (META.V).

Earnings & Valuation

This table compares Meta Growth Corp. (META.V) and Khiron Life Sciences Corp. (KHRN.V)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meta Growth Corp. (META.V)C$60.96 million0.54C$-50,412,840.00C($0.21)-0.66
Khiron Life Sciences Corp. (KHRN.V)C$8.01 million10.31C$-39,493,921.00C($0.26)-2.09

Khiron Life Sciences Corp. (KHRN.V) has lower revenue, but higher earnings than Meta Growth Corp. (META.V). Khiron Life Sciences Corp. (KHRN.V) is trading at a lower price-to-earnings ratio than Meta Growth Corp. (META.V), indicating that it is currently the more affordable of the two stocks.

Khiron Life Sciences Corp. (KHRN.V) (CVE:KHRN) and 48North Cannabis Corp. (NRTH.V) (CVE:NRTH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Khiron Life Sciences Corp. (KHRN.V) and 48North Cannabis Corp. (NRTH.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Khiron Life Sciences Corp. (KHRN.V)N/AN/AN/A
48North Cannabis Corp. (NRTH.V)N/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Khiron Life Sciences Corp. (KHRN.V) and 48North Cannabis Corp. (NRTH.V), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Khiron Life Sciences Corp. (KHRN.V)0000N/A
48North Cannabis Corp. (NRTH.V)0000N/A

Khiron Life Sciences Corp. (KHRN.V) currently has a consensus price target of C$1.20, suggesting a potential upside of 118.18%. Given Khiron Life Sciences Corp. (KHRN.V)'s higher probable upside, equities analysts plainly believe Khiron Life Sciences Corp. (KHRN.V) is more favorable than 48North Cannabis Corp. (NRTH.V).

Valuation and Earnings

This table compares Khiron Life Sciences Corp. (KHRN.V) and 48North Cannabis Corp. (NRTH.V)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Khiron Life Sciences Corp. (KHRN.V)C$8.01 million10.31C$-39,493,921.00C($0.26)-2.09
48North Cannabis Corp. (NRTH.V)C$13.55 million4.18C$-51,488,682.00C($0.26)-1.10

Khiron Life Sciences Corp. (KHRN.V) has higher earnings, but lower revenue than 48North Cannabis Corp. (NRTH.V). Khiron Life Sciences Corp. (KHRN.V) is trading at a lower price-to-earnings ratio than 48North Cannabis Corp. (NRTH.V), indicating that it is currently the more affordable of the two stocks.

Khiron Life Sciences Corp. (KHRN.V) (CVE:KHRN) and (CSI) (CNSX:CSI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Khiron Life Sciences Corp. (KHRN.V) and (CSI)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Khiron Life Sciences Corp. (KHRN.V)N/AN/AN/A
(CSI)N/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Khiron Life Sciences Corp. (KHRN.V) and (CSI), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Khiron Life Sciences Corp. (KHRN.V)0000N/A
(CSI)0000N/A

Khiron Life Sciences Corp. (KHRN.V) currently has a consensus price target of C$1.20, suggesting a potential upside of 118.18%.

Valuation and Earnings

This table compares Khiron Life Sciences Corp. (KHRN.V) and (CSI)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Khiron Life Sciences Corp. (KHRN.V)C$8.01 million10.31$-39,493,921.00C($0.26)-2.09
(CSI)N/AN/AN/AN/AN/A

(CSI) has lower revenue, but higher earnings than Khiron Life Sciences Corp. (KHRN.V).

Summary

Khiron Life Sciences Corp. (KHRN.V) beats (CSI) on 1 of the 1 factors compared between the two stocks.


Khiron Life Sciences Corp. (KHRN.V) Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
WLLW
Willow Biosciences Inc. (WLLW.TO)
1.1$1.62+8.0%C$184.70 millionC$2,360.00-5.77
LABS
MediPharm Labs Corp. (LABS.TO)
1.4$0.65+7.7%C$90.73 millionC$62.40 million-2.19
DN
Delta 9 Cannabis
1.4$0.56+3.6%C$57.14 millionC$48.48 million-13.66News Coverage
META
Meta Growth Corp. (META.V)
0.8$0.14+0.0%C$36.69 millionC$60.96 million-0.66Gap Up
NRTH
48North Cannabis Corp. (NRTH.V)
0.6$0.29+7.0%C$36.44 millionC$13.55 million-1.10Upcoming Earnings
CSI
(CSI)
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
IMCC
(IMCC)
0.0N/AN/A$0.00N/A0.00High Trading Volume
BAMM
28896
0.5N/AN/A$0.00N/A0.00High Trading Volume
ATT
Abattis Bioceuticals
0.5N/AN/AC$0.00N/A0.00Gap Down
AGRA
Agraflora Organics International
1.4N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
GRIN
Grindrod Shipping
1.7N/AN/A$0.00N/A0.00High Trading Volume
SPR
Spirit AeroSystems
0.5N/AN/A$0.00N/A0.00High Trading Volume
VIDA
Vidaroo
0.5N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.